AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Apellis Pharmaceuticals CEO Cedric Francois Sells $6.35 Million in Stock
ByAinvest
Saturday, Aug 30, 2025 3:45 am ET1min read
Apellis Pharmaceuticals CEO Cedric Francois sold 225,000 shares worth $6.35mln on August 29, 2025. The company achieved its third FDA approval in four years, expanding EMPAVELI's label and showing steady growth for SYFOVRE. However, challenges like high free goods utilization and co-pay assistance issues impacted revenue. Analysts have adjusted price targets for Apellis, reflecting both opportunities and challenges in its growth trajectory.
WALTHAM, Mass., July 2, 2025 — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has seen significant developments in its recent financial and operational landscape. On August 29, 2025, the company's CEO, Cedric Francois, sold 225,000 shares worth $6.35 million [3]. This move comes amidst a series of notable achievements and challenges for the biopharmaceutical company.Apellis Pharmaceuticals has recently achieved its third FDA approval in four years, expanding the label for its EMPAVELI treatment. This approval has shown steady growth for SYFOVRE, the company's therapy for geographic atrophy secondary to age-related macular degeneration (GA) [1]. The company's focus on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs has been a driving force behind its recent success [2].
However, the company has faced challenges such as high free goods utilization and co-pay assistance issues, which have impacted its revenue. These issues have led analysts to adjust their price targets for Apellis, reflecting both opportunities and challenges in its growth trajectory [3].
In light of these developments, Apellis Pharmaceuticals management will participate in upcoming investor conferences, providing insights into the company's future prospects. The live conference webcasts will be available on the company's website, with replays available for approximately 30 days following the events [1].
References:
[1] https://www.globenewswire.com/news-release/2025/08/27/3139859/0/en/Apellis-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html
[2] https://finance.yahoo.com/quote/APLS/
[3] https://www.marketscreener.com/news/apellis-pharmaceuticals-insider-sold-shares-worth-6-352-743-according-to-a-recent-sec-filing-ce7c50dddc8df026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet